Mass treatment to eliminate filariasis in Papua New Guinea

New England Journal of Medicine

Volumn 347, Issue 23, 2002, Pages 1841-1848

  Bockarie, Moses J ^a   Tisch, Daniel J ^b   Kastens, Will ^a,b   Alexander, Neal D E ^c   Dimber, Zachary ^a   Bockarie, Florence ^a   Ibam, Ervin ^a   Alpers, Michael P ^a,d   Kazura, James W ^b  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN;

ARTICLE; DISEASE CARRIER; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FILARIASIS; HUMAN; HYDROCELE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MICROFILARIA; MICROFILARIASIS; PAPUA NEW GUINEA; PARASITE TRANSMISSION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; WUCHERERIA BANCROFTI;

ADOLESCENT; ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; CULICIDAE; DIETHYLCARBAMAZINE; DISEASE RESERVOIRS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; IVERMECTIN; LYMPHEDEMA; MALE; PAPUA NEW GUINEA; PROSPECTIVE STUDIES; TESTICULAR HYDROCELE; WUCHERERIA BANCROFTI;

EID: 0037028058     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021309     Document Type: Article

References (45)

1. Behbehani K. Candidate parasitic diseases. Bull World Health Organ 1998;76:Suppl 2:64-7.
2. Dreyer G, Coelho G. Lymphatic filariasis: A potentially eradicable disease. Cad Saude Publica 1997;13:537-43. (In Portuguese.)
3. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999;15:382-6.
4. Ottesen EA. Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 1985;7:341-56.
5. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000;121:Suppl:S147-S160.
6. Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997;350:480-4. (Erratum, Lancet 1997;350:1036.]
7. Norman RA, Chan MS, Srividya A, et al. EPIFIL: The development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect 2000;124:529-41.
8. Plaisier AP, Subramanian S, Das PK, et al. The LYMFASIM simulation program for modeling lymphatic filariasis and its control. Methods Inf Med 1998;37:97-108.
9. Bockarie MJ, Alexander ND, Hyun P, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998;351:162-8.
10. Bockarie M, Kazura J, Alexander N, et al. Transmission dynamics of Wuchereria bancrofti in East Sepik Province, Papua New Guinea. Am J Trop Med Hyg 1996;54:577-81.
11. Michael E, Simonsen PE, Malecela M, et al. Transmission intensity and the immunoepidemiology of bancroftian filariasis in East Africa. Parasite Immunol 2001;23:373-88.
12. Smith PG, Morrow RH, eds. Methods for Field Trials of Intervention against Tropical Diseases: A "Toolbox." Oxford, England: Oxford University Press, 1991.
13. Kazura J, Greenberg J, Perry R, Weil G, Day K, Alpers M. Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. Am J Trop Med Hyg 1993;49:804-11.
14. Ottesen EA, Vijayasekaran V, Kumaraswami V, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990;322:1113-7.
15. Desowitz RS, Hitchcock JC. Hyperendemic bancroftian filariasis in the Kingdom of Tonga: The application of the membrane filter concentration technique to an age-stratified blood survey. Am J Trop Med Hyg 1974;23:877-9.
16. More SJ, Copeman DB. A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis. Trop Med Parasitol 1990;41:403-6.
17. WHO Expert Committee on Filariasis. Third report. WHO Tech Rep Ser 1974;542:1-54.
18. Bockarie MJ, Fischer P, Williams SA, et al. Application of a polymerase chain reaction-ELISA to detect Wuchereria bancrofti in pools of wild-caught Anopheles punctulatus in a filariasis control area in Papua New Guinea. Am J Trop Med Hyg 2000;62:363-7.
19. Hii JL, Smith T, Mai A, Ibam E, Alpers MP. Comparison between anopheline mosquitoes (Diptera: Cuhcidae) caught using different methods in a malaria endemic area of Papua New Guinea. Bull Entomol Res 2000;90:211-9.
20. Nelson GS. Staining of filarial larvae in insects before dissection. Bull World Health Organ 1958;19:204.
21. Walsh JF, Davies JB, Le Berre R, Grams R. Standardization of criteria for assessing the effect of Simulium control in onchocerciasis control programmes. Trans R Soc Trop Med Hyg 1978;72:675-6.
22. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
23. Weil GL, Lammie PJ, Richards FO Jr, Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis 1991;164:814-6.
24. Freedman DO, Plier DA, De Almeida AB, De Oliveira AL, Miranda J, Braga C. Effect of aggressive prolonged diethylcarbamazine therapy on circulating antigen levels in bancroftian filariasis. Trop Med Int Health 2001;6:37-41.
25. Tisch DJ, Hazlett FE, Kastens W, Alpers MP, Bockarie MJ, Kazura JW. Ecologic and biologic determinants of filarial antigenemia in bancroftian filariasis in Papua New Guinea. J Infect Dis 2001;184:898-904.
26. Dean M. At last, the fight against lymphatic filariasis begins. Lancet 2000;355:385.
27. Burkot T, Ichimori K. The PacELF programme: Will mass drug administration be enough? Trends Parasitol 2002;18:109-15.
28. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998;92:94-7.
29. Taylor MJ, Bandi C, Hoerauf AM, Lazdins J. Wolbachia bacteria of filarial nematodes: A target for control? Parasitol Today 2000;16:179-80.
30. Meyrowitsch DW, Simonsen PE, Makunde WH. Mass DEC chemotherapy for control of bancroftian filariasis: Comparative efficacy of four strategies two years after start of treatment. Trans R Soc Trop Med Hyg 1996;90:423-8.
31. Partono F. Treatment of elephantiasis in a community with timorian filariasis. Trans R Soc Trop Med Hyg 1985;79:44-6.
32. Kazura JW, Bockarie M, Alexander N, et al. Transmission intensity and its relationship to infection and disease due to Wuchereria bancrofti in Papua New Guinea. J Infect Dis 1997;176:242-6.
33. King CL. Transmission intensity and human immune responses to lymphatic filariasis. Parasite Immunol 2001;23:363-71.
34. Southgate BA, Bryan JH. Factors affecting transmission of Wuchereria bancrofti by anopheline mosquitoes. 4. Facilitation, limitation, proportionality and their epidemiological significance. Trans R Soc Trop Med Hyg 1992;86:523-30.
35. Webber RH. Vector control of filariasis in the Solomon Islands. Southeast Asian J Trop Med Public Health 1975;6:430-4.
36. Hawking F. The distribution of human filariasis throughout the world. II. Asia. Trop Dis Bull 1976;73:967-1016.
37. Pan PC. Filariasis eradication on Kinmen Proper, Kinmen (Quemoy) Islands, Republic of China. Acta Trop 1990;47:161-9.
38. Perolat P, Guidi C, Rivière F, Roux J. Filariose de bancroft Polynésie française: Situation épidémiologique et perspectives après 35 ans de lutte. Bull Soc Pathol Exot Filiales 1986;79:78-88.
39. Esterre P, Plichart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: The Maupiti cohort. Trop Med Int Health 2001;6:190-5.
40. Mataika JU, Kimura E, Koroivueta J, Shimada M. Efficacy of five annual single doses of diethylcarbamazine for treatment of lymphatic filariasis in Fiji. Bull World Health Organ 1998;76:575-9.
41. Maxwell CA, Curtis CF, Haji H, Kisumku S, Thalib AI, Yahya SA. Control of bancroftian filariasis by integrating therapy with vector control using polystyrene beads in wet pit latrines. Trans R Soc Trop Med Hyg 1990;84:709-14.
42. Zielke E, Chlebowsky HO. Studies on bancroftian filariasis in Liberia, West Africa. V. The influence of treatment with diethylcarbamazine and vector control on the transmission of Wuchereria bancrofti. Tropenmed Parasitol 1980;31:444-58.
43. Das PK, Ramaiah KD, Vanamail P, et al. Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans R Soc Trop Med Hyg 2001;95:336-41.
44. Rochet MJ. A simple deterministic model for bancroftian filariasis transmission dynamics. Trop Med Parasitol 1990;41:225-33.
45. Srividya A, Das PK, Subramanian S, et al. Past exposure and the dynamics of lymphatic filariasis infection in young children. Epidemiol Infect 1996;117:195-201.